LifeMD Reports Third Quarter 2025 Results Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted

Reports Third Quarter 2025 Results

call begins at 4:30 p.m. Eastern time today

YORK, November 17, 2025 - LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported

financial results for the three and nine months ended September 30, 2025.

third quarter of 2025 marked an important step forward for LifeMD," said Justin Schreiber, Chairman and CEO of LifeMD.

"While the weight management market remained challenging, driven largely by fierce competition from low-price compounded GLP-1

providers, our business continued to demonstrate real strength. We continued to on-board a significant volume of new weight

management patients per day supported by the power of our brand, our best-in-class care platform and our strategic partnerships. We

expect the GLP-1 market to evolve rapidly in the year to come as product innovation and improved pricing expand access, and we

believe LifeMD is uniquely positioned to capitalize on these trends and accelerate growth in 2026."

the same time, we are gaining significant traction in diversifying our platform. We are seeing strong early traction in behavioral health,

women's health, men's hormone therapy, and personalized compounded ED therapies. Our RexMD business returned to growth and

added nearly 10,000 net new subscribers in the quarter. We also achieved a major milestone with the regulatory approval of our Pennsylvania-based

503-A compounding pharmacy. We are currently licensed in 14 states and are aggressively pursuing licensure in all 50 states. This pharmacy

meaningfully strengthens our competitive positioning by expanding our ability to deliver personalized therapies, improving cost structure,

and enhancing the patient experience.

to quarter end, we completed the divestiture of our majority ownership in WorkSimpli, which transformed LifeMD into a pure-play virtual

care and pharmacy platform and significantly strengthened our balance sheet. As we look to 2026, we believe LifeMD remains very well

positioned with a strong balance sheet, an increasingly diversified virtual care and pharmacy platform and a full suite

of industry-leading capabilities to accelerate our growth," concluded Mr. Schreiber.

quarter results for our telehealth business on a stand-alone basis were solid with revenue increasing 18% and adjusted EBITDA

increasing 30% versus the prior year period. Importantly, our RexMD business returned to sequential growth in both revenue and patient

subscriber count. Additionally, we took major steps to significantly strengthen the company's balance sheet and liquidity including

paying off all outstanding debt and the divestiture of our majority interest in WorkSimpli subsequent to quarter end. We have also continued

to make significant strides in the company's ongoing telehealth business profitability with year-to-date telehealth Adjusted EBITDA

profitability up 294% versus year," said Marc Benathen, LifeMD's Chief Financial Officer.

Quarter Financial Highlights

comparisons are with the third quarter of 2024. Non-GAAP financial measures referenced below are defined and reconciled to GAAP financial

measures at the end of this press release.

Quarter Key Performance Metrics

the fourth quarter of 2025, the Company's guidance reflects revenue and adjusted EBITDA as a stand-alone telehealth company following

the WorkSimpli divestiture:

the full year 2025, the Company's guidance reflects revenue and adjusted EBITDA as a stand-alone telehealth company following the

WorkSimpli divestiture and reflecting a $1.1 million adjustment in 2025 related to the November 5, 2025 press release:

management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company's financial results and outlook,

and answer questions. Details for the call are as follows:

live and archived webcast will be available in the Investors section of the Company's website at ir.lifemd.com.

is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized

treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone

therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art

affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information,

please visit LifeMD.com.

Note Regarding Forward Looking Statements

news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section

21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform

Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: "believe,"

"expect," "anticipate," "project," "should," "plan," "will,"

"may," "intend," "estimate," predict," "continue," and "potential,"

or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking

statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance

and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving

regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the

effects of any of the foregoing on our future results of operations or financial condition.

statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations,

beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy,

and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements

relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult

to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may

differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited

to, "Risk Factors" identified in our filings with the Securities and Exchange Commission, including, but not limited to,

our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results,

performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative

of our actual results, performance, or financial condition in subsequent periods.

forward-looking statement made in the news release is based on information currently available to us as of the date on which this release

is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future

events, or otherwise, except as may be required under applicable law or regulation.

Benathen, Chief Financial Officer

Friedeman, Chief Marketing and Product Officer

STATEMENTS OF OPERATIONS

STATEMENTS OF CASH FLOWS

the Use of Non-GAAP Financial Measures:

supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify

and enhance an understanding of past performance. Additionally, we report telehealth adjusted EBITDA as a non-GAAP financial measure

to clarify the financial performance of our core telehealth business excluding WorkSimpli. We believe that the presentation of these

financial measures enhances an investor's understanding of our financial performance. We further believe that these financial measures

are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are

not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance

relative to that of our competitors.

EBITDA is defined as income (loss) attributable to common shareholders before interest, taxes, depreciation, amortization, accretion,

financing transaction expense, non-controlling interests, foreign currency translation, extraordinary litigation costs, loss on debt

extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses and stock-based

compensation expense. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to common shareholders, its

most directly comparable GAAP financial measure.

and WorkSimpli adjusted EBITDA is defined as segment operating income or loss before depreciation, amortization, accretion, financing

transaction expense, extraordinary litigation costs, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance

expenses and stock-based compensation expense. We have provided below a reconciliation of segment operating income or loss to segment

believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However,

our use of the terms adjusted EBITDA may vary from that of others in our industry. Telehealth adjusted EBITDA is specifically relevant

to LifeMD to provide shareholders a comparable measure of profitability for our core telehealth business without the impact of our majority

owned, but separately managed non-core subsidiary, WorkSimpli. Adjusted EBITDA, telehealth adjusted EBITDA and WorkSimpli adjusted EBITDA

should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures